Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | SCN4A | P35499 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5788640 | 0.84 | EPHX1 (0.50) | EPHX1ANPEPSIGMAR1SLC6A2TAAR1 | |
| SCHEMBL15539656 | 0.81 | TRPA1 (0.38) | SIGMAR1SLC6A2TAAR1MAOASLC6A4 | |
| SCHEMBL15540392 | 0.81 | TRPA1 (0.38) | SIGMAR1SLC6A2TAAR1MAOASLC6A4 | |
| SCHEMBL20285039 | 0.80 | GRIN2D (0.43) | TAAR1 | |
| SCHEMBL28580311 | 0.80 | GRIN2D (0.43) | TAAR1 | |
| SCHEMBL6504637 | 0.80 | SCN4A (0.40) | SCN4ATACR1 | |
| SCHEMBL12487435 | 0.80 | SCN4A (0.40) | SCN4ATACR1 | |
| SCHEMBL6504640 | 0.80 | SCN4A (0.40) | SCN4ATACR1 | |
| SCHEMBL6993568 | 0.78 | ANPEP (0.36) | ANPEP | |
| SCHEMBL16727131 | 0.77 | IDO1 (0.41) | EPHX1TACR1AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3160966-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | Effector Therapeutics Inc. (US) | 2017-05-03 | — | — | EP | disclosed |
| WO-2015200481-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. (US) | 2015-12-30 | — | — | WO | disclosed |